Bio-Rad Laboratories, Inc. $BIO Position Increased by Natixis Advisors LLC

Posted by on Jun 6th, 2026

Natixis Advisors LLC increased its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 9.0% in the 4th quarter, Holdings Channel.com reports. The fund owned 70,916 shares of the medical research company’s stock after buying an additional 5,847 shares during the quarter. Natixis Advisors LLC’s holdings in Bio-Rad Laboratories were worth $21,487,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Clear Harbor Asset Management LLC increased its position in Bio-Rad Laboratories by 57.7% during the fourth quarter. Clear Harbor Asset Management LLC now owns 2,419 shares of the medical research company’s stock worth $733,000 after buying an additional 885 shares during the last quarter. BNP Paribas Financial Markets increased its position in Bio-Rad Laboratories by 2,098.0% during the fourth quarter. BNP Paribas Financial Markets now owns 72,555 shares of the medical research company’s stock worth $21,983,000 after buying an additional 69,254 shares during the last quarter. Norges Bank acquired a new position in Bio-Rad Laboratories during the fourth quarter worth $34,600,000. Eurizon Capital SGR S.p.A. acquired a new position in Bio-Rad Laboratories during the fourth quarter worth $113,000. Finally, Savant Capital LLC acquired a new position in Bio-Rad Laboratories during the fourth quarter worth $210,000. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Stock Down 4.4%

NYSE BIO opened at $294.01 on Friday. The company has a current ratio of 3.21, a quick ratio of 2.37 and a debt-to-equity ratio of 0.12. The stock’s 50 day moving average is $282.12 and its two-hundred day moving average is $291.70. The company has a market capitalization of $7.87 billion, a price-to-earnings ratio of 48.44 and a beta of 1.08. Bio-Rad Laboratories, Inc. has a 1-year low of $219.42 and a 1-year high of $343.12.

Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $1.89 earnings per share for the quarter, missing analysts’ consensus estimates of $1.97 by ($0.08). The company had revenue of $592.10 million for the quarter, compared to analyst estimates of $589.91 million. Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%. The firm’s revenue for the quarter was up 1.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.54 earnings per share. Equities analysts forecast that Bio-Rad Laboratories, Inc. will post 9.42 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Wall Street Zen downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Citigroup downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $375.00 to $300.00 in a research report on Tuesday, April 7th. Royal Bank Of Canada started coverage on shares of Bio-Rad Laboratories in a research report on Friday, May 15th. They set an “outperform” rating and a $320.00 target price on the stock. Wells Fargo & Company lowered their price target on Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating on the stock in a research report on Friday, May 1st. Finally, Weiss Ratings downgraded Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, May 6th. One investment analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Bio-Rad Laboratories currently has a consensus rating of “Hold” and an average price target of $303.33.

View Our Latest Stock Report on Bio-Rad Laboratories

Bio-Rad Laboratories Company Profile

(Free Report)

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.

Read More

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.